News | December 30, 2021
Sanofi loses appeal in the US over Lantus device patents
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
It will be marketed under the brand name Molunamax
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
The product is expected to be available in a week’s time
DCGI approved the drug based on the review of clinical data
The company will market it under the brand name Molflu
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
The Home Healthcare market is expected to be US $ 14.2 by 2025
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
Subscribe To Our Newsletter & Stay Updated
